Do Cardiovascular Risk Factors Influence Cardiac Allograft Vasculopathy?

Kobashigawa, 2000, What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?, Curr Control Trials Cardiovasc Med, 1, 166, 10.1186/CVM-1-3-166 Labarrere, 1999, Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation, Curr Opin Cardiol, 14, 133, 10.1097/00001573-199903000-00010 Kapadia, 2000, Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging, J Heart Lung Transplant, 19, 167, 10.1016/S1053-2498(99)00128-X Tuzcu, 2005, Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation, J Am Coll Cardiol, 45, 1538, 10.1016/j.jacc.2004.12.076 Billingham, 1992, Histopathology of graft coronary disease, J Heart Lung Transplant, 11, S38 Lindenfeld, 2005, Drug therapy in the heart transplant recipient: Part III: common medical problems, Circulation, 111, 113, 10.1161/01.CIR.0000151609.60618.3C Rickenbacher, 1996, Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary untrasound study of immunologic and metabolic risk factors, Transplantation, 61, 46, 10.1097/00007890-199601150-00011 Eisen, 2003, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients, N Engl J Med, 349, 847, 10.1056/NEJMoa022171